bioRxiv · 10.1101/2025.04.01.646581
Disrupting Splicing Regulation to Rescue β-Catenin: A Novel Approach for Treating CTNNB1-Haploinsufficiency Disorder
Abstract
Loss-of-function mutations in the CTNNB1 gene cause {beta}-catenin deficiency, resulting in CTNNB1 syndrome--a rare neurodevelopmental disorder characterized by motor and cognitive impairments. Given the wide variety of mutations across CTNNB1 and its dosage sensitivity, a mutation-independent therapeutic approach that preserves endogenous gene regulation is critically needed. This study introduces spliceosome-mediated RNA trans-splicing as a novel approach to restore {beta}-catenin production. Precursor mRNA trans-splicing molecules (PTMs) targeting CTNNB1 introns 2, 5, and 6 were designed and evaluated using a split fluorescent YFP reporter system. Rationally designed short antisense RNAs, which mask splicing regulatory elements, significantly enhanced PTM-mediated trans-splicing at both RNA and protein levels. Additionally, introducing a self-cleaving ribozyme at the PTMs 5 end further improved trans-splicing efficiency, likely due to increased nuclear retention. CMV promoter-driven PTM expression yielded the highest efficiency. Importantly, successful trans-splicing of the endogenous CTNNB1 transcript confirmed the physiological relevance of this strategy. This study is the first to apply and optimize SMaRT for CTNNB1 correction, providing a promising, mutation-agnostic approach for treating CTNNB1 syndrome.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Maruna, M., Susjan Leite, P., Mesko, M., Jerala, R.. 2025-04-05. Disrupting Splicing Regulation to Rescue β-Catenin: A Novel Approach for Treating CTNNB1-Haploinsufficiency Disorder. https://doi.org/10.1101/2025.04.01.646581
Cite the original work for its findings. Save a collection to share your selection of sources.